IMPROVEMENT OF LONG-TERM PROGNOSIS IN PATIENTS WITH OVARIAN CANCERS BY ADJUVANT SIZOFIRAN IMMUNOTHERAPY - A PROSPECTIVE RANDOMIZED CONTROLLED-STUDY

The effect of immunotherapy using sizofiran (SPG) on the prognosis of patients with ovarian cancers was prospectively studied in a total of 68 patients, who were randomly assigned to either a cisplatin, adriamy cin and cyclophosphamide (PAC) therapy group or a PAC plus SPG combina tion therapy group. The survival rate was significantly higher in pati ents with stage Ic, II or III cancers treated with the PAC plus SPG co mbination, compared with the patients treated with PAC alone. In the S PG-receiving patients with stage Ic or more advanced cancers who were treated with four cycles or more of PAC, the outcome was improved (Cox -Mantel, p = 0.074; generalized Kruskal-Wallis, p = 0.032). Similar im provement was also observed in the patients with non-serous adenocarci nomas (Cox-Mantel, p-0.076; generalized Krukal-Wallis, p = 0.045). No side effects attributable to SPG were recorded. The present results su ggest that the use of SPG in combination with long-term chemotherapy i mproves the postoperative prognosis in ovarian cancer patients.